Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

286
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
286
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

1.8K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
1.8K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

160
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
160
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

181
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
181

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipid-lowering therapy after finding high Lp(a)-adding ezetimibe or intensifying statin treatment?

Journal of clinical lipidology·2026
Same author

Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement.

European heart journal·2026
Same author

Homozygous familial hypercholesterolaemia: insights from the Global HICC Registry.

European heart journal·2026
Same author

Global survey of genetic testing methods for familial hypercholesterolemia. A study and recommendations from the EAS FHSC registry.

European journal of preventive cardiology·2026
Same author

Lipoprotein(a) levels in Finnish adults: distribution and associations with other cardiovascular risk factors and their awareness and control.

Lipids in health and disease·2026
Same author

Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia.

European journal of preventive cardiology·2026

Related Experiment Video

Updated: Jan 4, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.4K

Statins for children with familial hypercholesterolemia.

Alpo Vuorio1, Jaana Kuoppala2, Petri T Kovanen3

  • 1University of Helsinki, Department of Forensic Medicine, Helsinki, Finland.

The Cochrane Database of Systematic Reviews
|November 8, 2019
PubMed
Summary

Statins effectively lower LDL cholesterol in children with familial hypercholesterolemia, with short-term safety appearing favorable. Long-term effects and safety require further investigation through extensive trials.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.0K

Related Experiment Videos

Last Updated: Jan 4, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.4K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.0K

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Pediatrics

Background:

  • Familial hypercholesterolemia (FH) is a common autosomal dominant inherited metabolic disorder affecting at least 1 in 500 individuals.
  • FH leads to premature atherosclerosis and cardiovascular disease, necessitating early childhood intervention.
  • Diagnosis in children involves elevated cholesterol levels or DNA analysis.

Purpose of the Study:

  • To evaluate the effectiveness and safety of statin therapy in children diagnosed with heterozygous familial hypercholesterolemia.
  • To provide an updated review of current evidence on statin use in pediatric FH patients.

Main Methods:

  • A systematic review of randomized placebo-controlled trials involving children up to 18 years old.
  • Studies compared statin treatment against placebo or diet alone.
  • Data extraction and study assessment were performed independently by two authors.

Main Results:

  • Nine randomized placebo-controlled studies with 1177 participants were included.
  • Statins demonstrated high-quality evidence for reducing low-density lipoprotein cholesterol levels.
  • Low-quality evidence suggested no significant differences in liver function or myopathy; moderate-quality evidence indicated few clinical adverse events.

Conclusions:

  • Statin therapy is an effective lipid-lowering treatment for children with FH, showing short-term safety.
  • Long-term safety of statins in this pediatric population remains undetermined.
  • Further large-scale, long-term randomized controlled trials are essential to establish definitive long-term safety profiles.